Fresenius Medical Care (NYSE:FMS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report report published on Monday. The brokerage issued a strong-buy rating on the stock.

Separately, Truist Financial reduced their price target on shares of Fresenius Medical Care from $24.00 to $22.00 and set a hold rating for the company in a research note on Wednesday, July 31st. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Fresenius Medical Care has a consensus rating of Hold and a consensus target price of $22.00.

Fresenius Medical Care Price Performance

Shares of NYSE FMS opened at $20.75 on Monday. Fresenius Medical Care has a 1-year low of $16.37 and a 1-year high of $22.76. The firm has a market capitalization of $12.18 billion, a PE ratio of 23.31, a P/E/G ratio of 1.08 and a beta of 0.90. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. The business’s fifty day moving average price is $19.76 and its two-hundred day moving average price is $19.99.

Fresenius Medical Care (NYSE:FMS) last posted its earnings results on Tuesday, July 30th. The company reported $0.38 EPS for the quarter, meeting the consensus estimate of $0.38. The firm had revenue of $5.13 billion for the quarter, compared to analysts’ expectations of $5.28 billion. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. On average, research analysts expect that Fresenius Medical Care will post 1.51 EPS for the current year.

Institutional Investors Weigh In On Fresenius Medical Care

Institutional investors and hedge funds have recently modified their holdings of the stock. Kimelman & Baird LLC purchased a new stake in shares of Fresenius Medical Care in the 2nd quarter valued at approximately $186,000. Creative Planning boosted its position in Fresenius Medical Care by 18.9% during the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after acquiring an additional 6,373 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Fresenius Medical Care in the second quarter worth approximately $197,000. Marshall Wace LLP grew its position in Fresenius Medical Care by 8.5% during the second quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock valued at $293,000 after purchasing an additional 1,207 shares in the last quarter. Finally, XTX Topco Ltd increased its stake in Fresenius Medical Care by 82.1% in the 2nd quarter. XTX Topco Ltd now owns 23,282 shares of the company’s stock valued at $444,000 after buying an additional 10,497 shares during the period. 8.25% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.